Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04467021 · ClinicalTrials.gov registry record · NA

Cancer and Blood Pressure Management, CARISMA Study

A NA study of Chronic Kidney Disease and Metastatic Renal Cell Carcinoma, sponsored by ECOG-ACRIN Cancer Research Group.

Active
Registry status
NA
Development phase
61
Enrollment target
20
Study locations

NCT04467021: Active NA study of Chronic Kidney Disease and Metastatic Renal Cell Carcinoma, sponsored by ECOG-ACRIN Cancer Research Group.

NCT04467021 is a NA study of Chronic Kidney Disease and Metastatic Renal Cell Carcinoma that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 61 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04467021, a NA study of Chronic Kidney Disease and Metastatic Renal Cell Carcinoma, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
61 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial studies how well intensive blood pressure management works in decreasing systolic blood pressure in patients with kidney or thyroid cancer that has spread to other places in the body (metastatic) who are starting anti-angiogenic tyrosine kinase inhibitor cancer therapy. This study is being done to find out if a systolic blood pressure to a target of less than 120 mmHg (intensive systolic blood pressure management) can be achieved, well tolerated, and beneficial as compared to the usual approach to a target of less than 140 mmHg while taking an anti-angiogenic tyrosine kinase inhibitor. This study may help doctors understand the best way to control blood pressure in kidney or thyroid cancer patients taking anti-angiogenic tyrosine kinase inhibitor.

Primary Outcome

Differences in SBP over the 6- month study period between intensive BP control (intervention) versus standard care (non-intervention group) will be compared using the "difference-indifference" method. All mixed effects models will be estimated using generalized estimating equations (GEE).

Conditions Studied

Chronic Kidney Disease Metastatic Renal Cell Carcinoma Stage IV Renal Cell Cancer AJCC v8 Cardiovascular Disorder Stage IV Thyroid Gland Medullary Carcinoma AJCC v8 Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8 Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8 Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8 Metastatic Thyroid Gland Medullary Carcinoma

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • OTHER Best Practice
  • OTHER Blood Pressure Measurement
  • OTHER Clinical Management

Study Locations (20)

Wisconsin

  • Aurora Cancer Care-Southern Lakes VLCC - Burlington
  • Aurora Saint Luke's South Shore - Cudahy
  • Aurora Health Care Germantown Health Center - Germantown
  • Aurora Cancer Care-Grafton - Grafton
  • Aurora BayCare Medical Center - Green Bay
  • Aurora Cancer Care-Kenosha South - Kenosha
  • Aurora Bay Area Medical Group-Marinette - Marinette
  • Aurora Cancer Care-Milwaukee - Milwaukee
  • Aurora Saint Luke's Medical Center - Milwaukee
  • Aurora Sinai Medical Center - Milwaukee
  • Vince Lombardi Cancer Clinic - Oshkosh - Oshkosh
  • Aurora Cancer Care-Racine - Racine

New York

  • Montefiore Medical Center-Einstein Campus - The Bronx
  • Montefiore Medical Center-Weiler Hospital - The Bronx
  • Montefiore Medical Center - Moses Campus - The Bronx

Missouri

  • Siteman Cancer Center at West County Hospital - Creve Coeur
  • Washington University School of Medicine - St Louis

Pennsylvania

  • University of Pennsylvania/Abramson Cancer Center - Philadelphia
  • University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh

Texas

  • UT Southwestern/Simmons Cancer Center-Dallas - Dallas

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2020-10-29
Est. Completion 2026-08-31
Phase NA
ECOG-ACRIN Cancer Research Group

75 total trials

What the registry record for NCT04467021 still lists

NCT04467021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (98% lower).

The record links to 9 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.

NCT04467021 names 20 study sites across 5 states, led by Wisconsin, New York, Missouri.

Frequently Asked Questions

What is clinical trial NCT04467021 about?

NCT04467021 is a clinical study titled "Cancer and Blood Pressure Management, CARISMA Study". This phase II trial studies how well intensive blood pressure management works in decreasing systolic blood pressure in patients with kidney or thyroid cancer that has spread to other places in the body (metastatic) who are starting anti-angiogenic tyrosine kinase inhibitor cancer therapy. This stud...

What is the current status of trial NCT04467021?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 61 participants. The study started on 2020-10-29. Estimated completion is 2026-08-31.

What conditions does trial NCT04467021 study?

This clinical trial studies the following conditions: Chronic Kidney Disease, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Cardiovascular Disorder, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8.

What interventions are being tested in trial NCT04467021?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Best Practice (OTHER), Blood Pressure Measurement (OTHER), Clinical Management (OTHER).

Who is sponsoring clinical trial NCT04467021?

This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04467021 being conducted?

This trial has 20 study locations across Missouri, New York, Pennsylvania, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04467021's enrollment target sits among peer trials

61 68th of 101 higher than 34 of 101 other Chronic Kidney Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04115306 · 61 participants · Phase 1

    Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

  • NCT05070845 · 61 participants · Phase 2

    Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

  • NCT05187832 · 61 participants · Phase 1

    A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

  • NCT05269316 · 61 participants · Phase 1

    Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04467021, the US trial registry maintained by the National Library of Medicine. NCT04467021 (small enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.